Risedronate Sodium Tablets — Class III drug recall D-0762-2022
Terminated recall by Macleods Pharma Usa Inc, reported 2022-04-13, distributed nationwide. FAILED CONTENT UNIFORMITY SPECIFICATIONS
| Recall number | D-0762-2022 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Macleods Pharma Usa Inc, Plainsboro, NJ, United States |
| Recall initiated | 2022-03-10 |
| Classified | 2022-04-07 |
| Reported by FDA | 2022-04-13 |
| Terminated | 2023-06-29 |
| Distributed | Nationwide (US) |
| Quantity | 4,872 bottles |
| NDC | 33342-0107, 33342-0107-06, 33342-0107-07, 33342-0107-49, 33342-0108, 33342-0108-06, 33342-0108-07, 33342-0108-15, 33342-0109, 33342-0109-37, 33342-0109-50 |
| Lot numbers | BRD2001A |
| Expiration dates | 2022-05 |
Product
Risedronate Sodium Tablets, USP, 5 mg, Rx Only, 30-count bottle, Manufactured for: Macleods Pharma USA, Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd., BAddi, HImchal Pradesh, INDIA, NDC 33342-107-07.
Reason for recall
FAILED CONTENT UNIFORMITY SPECIFICATIONS
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0762-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.